Patienterne skal overvåges nøje for at sikre, at der anvendes den lavest godkendte Aranesp- dosis til at kontrollere symptomerne på anæmi i tilstrækkelig grad.
Patients should be monitored closely to ensure that the lowest approved dose of Aranesp is used to provide adequate control of the symptoms of anaemia.